This company has shut down. Global Blood Therapeutics is no longer operating — its last tracked round was a Post-IPO Debt in 2021.
Explore the Startup GraveyardGBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Global Blood Therapeutics has raised $300.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in December 2021.
Global Blood Therapeutics's investors include RA Capital Management, Wellington Management, Third Rock Ventures, Deerfield, Cowen Healthcare Investments.
Global Blood Therapeutics is headquartered in South San Francisco, United States.
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Global Blood Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Global Blood Therapeutics — Funding & Investors." VCBacked, December 15, 2021, https://www.vcbacked.co/company/global-blood-therapeutics. Accessed August 13, 2026.
VCBacked. (2021). Global Blood Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/global-blood-therapeutics
{{cite web |title=Global Blood Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/global-blood-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated